Review of the Phytochemistry and Pharmacological Properties of Valeriana officinalis

Author(s): Omar Husham Ahmed Al-Attraqchi, Pran Kishore Deb*, Noor Husham Ahmed Al-Attraqchi

Journal Name: Current Traditional Medicine

Volume 6 , Issue 4 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

The extracts of Valeriana officinalis (V. officinalis) are among the most widely used herbal medications worldwide. The roots of this medicinal plant have been shown to be rich in a diverse set of phytochemicals that are biologically active. Various classes of chemical compounds are present in the roots of V. officinalis including, terpenes valepotriates and lignans. The high amount of bioactive chemical components in the extracts of this plant gives it potential medicinal applications in different pathological conditions such as sleep disorders, cardiovascular diseases, anxiety and depression. The most common medicinal use of V. officinalis extract is for the treatment of insomnia and improving the quality of sleep. Mild sedative effects of the extract, as well as the absence of any significant side effects, make it a popular alternative to the synthetic sedative drugs which are usually associated with undesirable adverse effects. In this review, the bioactive chemical components of V. officinalis and their pharmacological activities are highlighted. Also, the medicinal applications of valerian (V. officinalis) extracts and the possible mechanisms of action for the activities are discussed.

Keywords: Valeriana officinalis, valerian, valerenic acid, valepotriates, bioactive, sedative drugs.

[1]
Circosta C, De Pasquale R, Samperi S, Pino A, Occhiuto F. Biological and analytical characterization of two extracts from Valeriana officinalis. J Ethnopharmacol 2007; 112(2): 361-7.
[2]
Nandhini S, Narayanan K, Ilango K. Valeriana Officinalis: A review of its traditional uses, phytochemistry and pharmacology. Asian J Pharma Clin Res 2018; 11(1): 36-41.
[3]
Wang Y, Jin L, Yu S, Shi Q, Gu Y, Kiyota H. Chemical constituents of plants from the genus valeriana. Mini-Rev Org Chem 2010; 7(2): 161-72.
[4]
Schumacher B, Scholle S, Hölzl J, Khudeir N, Hess S, Müller CE. Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A1 adenosine receptors. J Nat Prod 2002; 65(10): 1479-85.
[5]
Abourashed A, Koetter U, Brattström A. In vitro binding experiments with a Valerian, hops and their fixed combination extract (Ze91019) to selected central nervous system receptors. Phytomedicine 2004; 11(7-8): 633-8.
[6]
Pereira RP, Fachinetto R, de Souza Prestes A, et al. Valeriana officinalis ameliorates vacuous chewing movements induced by reserpine in rats. J Neural Transm 2011; 118(11): 1547-57.
[7]
Santos G, Giraldez-Alvarez LD, Ávila-Rodriguez M, et al. SUR1 receptor interaction with hesperidin and linarin predicts possible mechanisms of action of valeriana officinalis in Parkinson. Front Aging Neurosci 2016; 8: 97.
[8]
Bent S, Padula A, Moore D, Patterson M, Mehling W. Valerian for sleep: a systematic review and metaanalysis. Am J Med 2006; 119(12): 1005-12.
[9]
Murti K, Kaushik M, Sangwan Y, Kaushik A. Pharmacological properties of Valeriana officinalis – A review. Pharmacologyonline 2011; 3: 641-6.
[10]
Klich R. [Behavior disorders in childhood and their therapy]. Die Medizinische Welt 1975; 26(25): 1251-4.
[11]
Plushner SL. Valerian: Valeriana officinalis. Am J Health-System Pharm 2000; 57(4): 328-5.
[12]
Pilerood SA, Prakash J. Nutritional and medicinal properties of valerian (Valeriana officinalis) herb: A review. Int J Food Nutr Dietetics 2013; 1(1): 25.
[13]
Lefebvre T, Foster BC, Drouin CE, Krantis A, Livesey JF, Jordan S. In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharm Sci 2004; 7(2): 265-73.
[14]
Jiang X, Zhang J, Liu Y, Fang Y. [Studies on chemical constituents of Valeriana officinalis]. Zhong Yao Cai Zhongyaocai J Chinese Med Mate 2007; 30(11): 1391-3.
[15]
Thies P. [On the chromomgenic behavior of valepotriate. 5. Report on the active substances of Valerian]. Arzneimittel-Forschung 1969; 19(3): 319.
[16]
Şen B, Mat A. Chemical and medicinal evaluations of the Valeriana species in Turkey İstanbul Üniversitesi Eczacılık Fakültesi Dergisi 2015; 45(2): 267-76.
[17]
Hazelhoff B. Phytochemical and pharmacological aspects of valerian compounds: With special reference to valepotriates: Rijksuniversiteit te Groningen; 1984.
[18]
Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 1999; 51(5): 505-12.
[19]
Andreatini R, Sartori VA, Seabra ML, Leite JR. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo controlled pilot study. Phytother Res Int J Devoted Pharmacol Toxicol Evaluation Nat Prod Derivatives 2002; 16(7): 650-4.
[20]
Lacher SK, Mayer R, Sichardt K, Nieber K, Müller CE. Interaction of valerian extracts of different polarity with adenosine receptors: identification of isovaltrate as an inverse agonist at A1 receptors. Biochem Pharmacol 2007; 73(2): 248-58.
[21]
Veith J, Schneider G, Lemmer B, Willems M. [The effect of degradation products of valepotriates on the motor activity of light-dark synchronized mice]. Planta Med 1986; 1(3): 179-83.
[22]
Wagner H, Jurcic K, Schaette R. Vergleichende Untersuchungen über die sedierende Wirkung von Baldrianextrakten, Valepotriaten und ihren Abbauprodukten. Planta Med 1980; 39(08): 358-65.
[23]
Schneider G, Willems M. Weitere Erkenntnisse über die Abbauprodukte der Valepotriate aus Kentranthus ruber (L.) DC. Archiv der Pharmazie 1982; 315(8): 691-7.
[24]
Bos R, Woerdenbag HJ, Pras N. Determination of valepotriates. J Chromatogr A 2002; 967(1): 131-46.
[25]
Torssell K, Wahlberg K. Isolation, structure and synthesis of alkaloids from Valeriana officinalis L. Acta Chem Scand 1967; 21: 53-62.
[26]
Zhang H-Y, Yang D-P, Ji H-F. Naturally occurring multipotent anti-Alzheimer’s agents. Expert Opin on Drug Discov 2006; 1(3): 269-77.
[27]
Wang P-C, Ran X-H, Luo H-R, et al. Phenolic compounds from the roots of Valeriana officinalis var. latifolia. J Braz Chem Soc 2013; 24(9): 1544-8.
[28]
Müller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta (BBA)-Biomembranes 2011; 1808(5): 1290-308.
[29]
Do KH, Choi YW, Kim EK, et al. Pinoresinol-4,4′-di-O-β-D-glucoside from Valeriana officinalis root stimulates calcium mobilization and chemotactic migration of mouse embryo fibroblasts. Phytomedicine 2009; 16(6-7): 530-7.
[30]
Wang PC, Ran XH, Chen R, et al. Sesquiterpenoids and lignans from the roots of Valeriana officinalis L. Chem Biodivers 2011; 8(10): 1908-13.
[31]
Sivasubramanian R. Effect of Valerian Root Extracts (Valeriana officinalis) on Acetaminophen Glucuronidation: In vitro and In vivo Studies. University of Pittsburgh 2005.
[32]
Trauner G, Khom S, Baburin I, Benedek B, Hering S, Kopp B. Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid. Planta Med 2008; 74(01): 19-24.
[33]
Tian J, Dang H, Middleton B, Kaufman DL. Clinically applicable GABA receptor positive allosteric modulators promote ß-cell replication. Sci Rep 2017; 7(1): 374.
[34]
Neuhaus W, Trauner G, Gruber D, et al. Transport of a GABAA receptor modulator and its derivatives from Valeriana officinalis L. S. l. Across an in vitro cell culture model of the blood-brain barrier. Planta Med 2008; 74(11): 1338-44.
[35]
Dietz BM, Mahady GB, Pauli GF, Farnsworth NR. Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. Mol Brain Res 2005; 138(2): 191-7.
[36]
Moore RY. Suprachiasmatic nucleus in sleep-wake regulation. Sleep Med 2007; 8: 27-33.
[37]
Patočka J, Jakl J. Biomedically relevant chemical constituents of Valeriana officinalis. J Appl Biomed 2010; 8(1): 11-8.
[38]
Fernández S, Wasowski C, Paladini AC, Marder M. Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalis. Pharmacol Biochem Behav 2004; 77(2): 399-404.
[39]
Wojdyło A, Oszmiański J, Czemerys R. Antioxidant activity and phenolic compounds in 32 selected herbs. Food Chem 2007; 105(3): 940-9.
[40]
Zheng W, Wang SY. Antioxidant activity and phenolic compounds in selected herbs. J Agric Food Chem 2001; 49(11): 5165-70.
[41]
Sateia MJ, Doghramji K, Hauri PJ, Morin CM. Evaluation of chronic insomnia. An American Academy of Sleep Medicine review. Sleep 2000; 23(2): 243-308.
[42]
Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002; 6(2): 97-111.
[43]
Taibi DM, Vitiello MV, Barsness S, Elmer GW, Anderson GD, Landis CA. A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia. Sleep Med 2009; 10(3): 319-28.
[44]
Taavoni S, Ekbatani N, Kashaniyan M, Haghani H. Effect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trial. Menopause 2011; 18(9): 951-5.
[45]
Dimpfel W, Suter A. Sleep improving effects of a single dose administration of a valerian/hops fluid extract. A double blind, randomized, placebo-controlled sleep-EEG study in a parallel design using the electrohypnogram. Zeitschrift für Phytotherapie 2008; 29(S1): P06.
[46]
Jacobs BP, Bent S, Tice JA, Blackwell T, Cummings SR. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Med 2005; 84(4): 197-207.
[47]
Koetter U, Schrader E, Käufeler R, Brattström A. A randomized, double blind, placebo controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. Phytother Res Int J Devoted Pharmacol Toxicol Evaluation Nat Prod Derivatives 2007; 21(9): 847-51.
[48]
Leathwood PD, Chauffard F, Heck E, Munoz-Box R. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav 1982; 17(1): 65-71.
[49]
Khadivzadeh T, Abdolahian S, Ghazanfarpour M, Kargarfard L, Dizavandi FR, Khorsand I. A systematic review and meta-analysis on the effect of herbal medicine to manage sleep dysfunction in pre and postmenopause. J Menopausal Med 2018; 24(2): 92-9.
[50]
Culpepper L, Wingertzahn MA. Over-the-counter agents for the treatment of occasional disturbed sleep or transient insomnia: A systematic review of efficacy and safety. The primary care companion for CNS disord 2015; 17(6)
[51]
Sarris J, Byrne GJ. A systematic review of insomnia and complementary medicine. Sleep Med Rev 2011; 15(2): 99-106.
[52]
Leach MJ, Page AT. Herbal medicine for insomnia: A systematic review and meta-analysis. Sleep Med Rev 2015; 24: 1-12.
[53]
Salter S, Brownie S. Treating primary insomnia - The efficacy of valerian and hops. Aust Fam Physician 2010; 39(6): 433-7.
[54]
Kennedy D, Little W, Scholey A. editors. Anxiolytic Effects of a Combination of Melissa officinalis and Valerlana officinalis During Laboratory Induced Stress. J Psychopharmacol; 2004: Sage Publications Ltd 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England.
[55]
Fajemiroye JO, da Silva DM, de Oliveira DR, Costa EA. Treatment of anxiety and depression: medicinal plants in retrospect. Fundam Clin Pharmacol 2016; 30(3): 198-215.
[56]
Ortiz JG, Nieves-Natal J, Chavez P. Effects of Valeriana officinalis extracts on [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. Neurochem Res 1999; 24(11): 1373-8.
[57]
Becker A, Felgentreff F, Schröder H, Meier B, Brattström A. The anxiolytic effects of a Valerian extract is based on valerenic acid. BMC Complement Altern Med 2014; 14(1): 267.
[58]
Neamati A, Chaman F, Hosseini M, Boskabady MH. The effects of Valeriana officinalis L. hydro-alcoholic extract on depression like behavior in ovalbumin sensitized rats. J Pharm Bioallied Sci 2014; 6(2): 97.
[59]
Savage K, Firth J, Stough C, Sarris J. GABA-modulating phytomedicines for anxiety: A systematic review of preclinical and clinical evidence. Phytother Res 2018; 32(1): 3-18.
[60]
Pakseresht S, Boostani H, Sayyah M. Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study. J Complement Integr Med 2011; 8(1)
[61]
Dimmeler S. Cardiovascular Disease Review Series. EMBO Press 2011.
[62]
Chen H-W, Wei B-J, He X-H, Liu Y, Wang J. Chemical components and cardiovascular activities of Valeriana spp. Evid Based Complement Alternat Med 2015; 2015: 1-11.
[63]
Sehgel NL, Zhu Y, Sun Z, et al. Increased vascular smooth muscle cell stiffness: a novel mechanism for aortic stiffness in hypertension. Am J Physiol Heart Circ Physiol 2013; 305(9): H1281-7.
[64]
Zhou XZ, Kang L, Tang Y, Li L, Xiong SH. Effect of Valeriana Officinalis, Var Latifolia Miq on heart rate and arterial blood pressure of rabbite. J Liaoning University Tradit Chin Med 2009; 11: 188-9.
[65]
Snider ME, Nuzum DS, Veverka A. Long-acting nifedipine in the management of the hypertensive patient. Vasc Health Risk Manag 2008; 4(6): 1249.
[66]
Sharma S, Dixit V. Epilepsy - A comprehensive review. Int J Pharma Res Rev 2013; 2(12): 61-80.
[67]
Fan H-C, Lee H-S, Chang K-P, et al. The impact of anti-epileptic drugs on growth and bone metabolism. Int J Mol Sci 2016; 17(8): 1242.
[68]
Hiller KO, Zetler G. Neuropharmacological studies on ethanol extracts of Valeriana officinalis L.: Behavioural and anticonvulsant properties. Phytother Res 1996; 10(2): 145-51.
[69]
Rezvani ME, Roohbakhsh A, Allahtavakoli M, Shamsizadeh A. Anticonvulsant effect of aqueous extract of Valeriana officinalis in amygdala-kindled rats: possible involvement of adenosine. J Ethnopharmacol 2010; 127(2): 313-8.
[70]
Nirmala RC, Gopalakrishnan V. Phytochemical, admet and docking studies on Valeriana Officinalis for predicting antiepilpetic drug molecules. Bioinform 2013; 2(7)
[71]
Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2014; 29(13): 1583-90.
[72]
Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. Jama 2014; 311(16): 1670-83.
[73]
Sudati JH, Fachinetto R, Pereira RP, et al. In vitro antioxidant activity of Valeriana officinalis against different neurotoxic agents. Neurochem Res 2009; 34(8): 1372.
[74]
de Oliveria DM, Barreto G, De Andrade DVG, et al. Cytoprotective effect of Valeriana officinalis extract on an in vitro experimental model of Parkinson disease. Neurochem Res 2009; 34(2): 215-20.
[75]
Wallace S, Keightley A, Gie C. Dysmenorrhoea. The Obstet Gynaecol 2010; 12(3): 149-54.
[76]
Occhiuto F, Pino A, Palumbo DR, et al. Relaxing effects of Valeriana officinalis extracts on isolated human non-pregnant uterine muscle. J Pharm Pharmacol 2009; 61(2): 251-6.
[77]
Mirabi P, Dolatian M, Mojab F, Majd HA. Effects of valerian on the severity and systemic manifestations of dysmenorrhea. Int J Gynaecol Obstet 2011; 115(3): 285-8.
[78]
Jenabi E, Asle Toghiri M, Hejrati P. The comparison of the effects of antiplain of Valeriana officinalis risom and mefenamic acid in relief of primary dismenorrhea. The Iran J Obstet Gynecol Infertil 2012; 15(2): 42-7.
[79]
Malva JO, Santos S, Macedo T. Neuroprotective properties of Valeriana officinalis extracts. Neurotox Res 2004; 6(2): 131-40.
[80]
Kumar GP, Khanum F. Neuroprotective potential of phytochemicals. Pharmacogn Rev 2012; 6(12): 81.
[81]
Yoo DY, Jung HY, Nam SM, et al. Valeriana officinalis extracts ameliorate neuronal damage by suppressing lipid peroxidation in the Gerbil hippocampus following transient cerebral ischemia. J Med Food 2015; 18(6): 642-7.
[82]
Anderson GD, Elmer GW, Kantor ED, Templeton IE, Vitiello MV. Pharmacokinetics of valerenic acid after administration of valerian in healthy subjects. Phytother Res 2005; 19(9): 801-3.
[83]
Anderson GD, Elmer GW, Taibi DM, et al. Pharmacokinetics of valerenic acid after single and multiple doses of valerian in older women. Phytother Res 2010; 24(10): 1442-6.
[84]
Carrasco MC, Vallejo JR, Pardo-de-Santayana M, Peral D, Martín MÁ, Altimiras J. Interactions of Valeriana officinalis L. and Passiflora incarnata L. in a patient treated with lorazepam. Phytother Res 2009; 23(12): 1795-6.
[85]
Dalla Corte C, Fachinetto R, Colle D, et al. Potentially adverse interactions between haloperidol and valerian. Food Chem Toxicol 2008; 46(7): 2369-75.
[86]
Al Atraqchi NH, Hamed WM. Preliminary phytochemical screening and in vitro evaluation of antioxidant activity of Iraqi species of silybum marianum seeds. Int Res J Pharm 2015; 5(5): 378-83.
[87]
Donovan JL, DeVane CL, Chavin KD, et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 2004; 32(12): 1333-6.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 6
ISSUE: 4
Year: 2020
Published on: 30 July, 2020
Page: [260 - 277]
Pages: 18
DOI: 10.2174/2215083805666190314112755
Price: $25

Article Metrics

PDF: 22
HTML: 2
EPUB: 1
PRC: 1